September 7, 2017 / 12:01 PM / 3 months ago

FDA puts Celgene's multiple cancer trials on hold

Sept 7 (Reuters) - Celgene Corp said on Thursday the U.S. Food and Drug Administration had placed a partial clinical hold on the company’s five trials and a full clinical hold on one trial.

The trials are testing AstraZeneca Plc’s key immunotherapy, Imfinzi, in combination with chemical agents, with or without chemotherapy, in blood cancers such as multiple myeloma, chronic lymphocytic leukaemia and lymphoma. (Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by Maju Samuel)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below